血液透析病人高磷血症的治疗进展(5)
21. Curtin RB, svarstad BL, amdress D, Keller t, Sacksteder P. Differences in older versus younger hemodialysis patients' noncompliance with oral medications. Geriatr Nephrol Urol 1997;7:35-44.
22. Jnssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluninum hydroxide, calcium carbonate and calcium actate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45:111-119.
23. Moriniere, P, Boudailliez B, et al. Prevention of osteitis fibrosa. Aluminum bone disease and softtissue calcification in dialysis patients: A long-term comparison of modrate doses of oral calcium±Mg(OH)2 vs.Al(OH)3±1 alpha OH vitamin D3.Nephrol Dial Transpl 1989;4:1045-1053.
24. Delmez JA, Slatopolsky E. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303-317.
25. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, donder in patients on hemodialysis, Clin Nephrol 1987; 28:180-185.
26. Breuer J, Moniz C, Baldwin D, Parsons V. the effects of zero magnesium dialysate and magnesium supplements of ionized calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transpl 1987;2:347-350.
27. Delmez JA, Kelber J, Norword KY, Giles KS, slatopolsky E.Magneium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-167.
28. Norris KC. Toward A new treatment paradigm for hyperphatemia in chronic renal disease. Dial & Transpl 1998;27:767-73., 百拇医药(王世相综述 管德林审校相综述 管德林审校)
22. Jnssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluninum hydroxide, calcium carbonate and calcium actate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45:111-119.
23. Moriniere, P, Boudailliez B, et al. Prevention of osteitis fibrosa. Aluminum bone disease and softtissue calcification in dialysis patients: A long-term comparison of modrate doses of oral calcium±Mg(OH)2 vs.Al(OH)3±1 alpha OH vitamin D3.Nephrol Dial Transpl 1989;4:1045-1053.
24. Delmez JA, Slatopolsky E. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303-317.
25. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, donder in patients on hemodialysis, Clin Nephrol 1987; 28:180-185.
26. Breuer J, Moniz C, Baldwin D, Parsons V. the effects of zero magnesium dialysate and magnesium supplements of ionized calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transpl 1987;2:347-350.
27. Delmez JA, Kelber J, Norword KY, Giles KS, slatopolsky E.Magneium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49: 163-167.
28. Norris KC. Toward A new treatment paradigm for hyperphatemia in chronic renal disease. Dial & Transpl 1998;27:767-73., 百拇医药(王世相综述 管德林审校相综述 管德林审校)